Abstract
Over the last decade, advancements in massively-parallel DNA sequencing and computational biology have allowed for unprecedented insights into the fundamental mutational processes that underlie virtually every major cancer type. Two major cancer genomics consortia—The Cancer Genome Atlas (TCGA) and the International Cancer Genome Consortium (ICGC)—have produced rich databases of mutational, pathological, and clinical data that can be mined through web-based portals, allowing for correlative studies and testing of novel hypotheses on well-powered patient cohorts.
In this chapter, we will review the impact of these technological developments on the understanding of molecular subtypes that promote prostate cancer initiation, progression, metastasis, and clinical aggression. In particular, we will focus on molecular subtypes that define clinically-relevant patient cohorts and assess how a better understanding of how these subtypes—in both somatic and germline genomes—may influence the clinical course for individual men diagnosed with prostate cancer.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
E.S. Lander, L.M. Linton, B. Birren, C. Nusbaum, M.C. Zody, J. Baldwin, et al., Initial sequencing and analysis of the human genome. Nature 409, 860–921 (2001)
S. Baichoo, C.A. Ouzounis, Computational complexity of algorithms for sequence comparison, short-read assembly and genome alignment. Biosystems 156-157, 72–85 (2017)
T.J. Ley, E.R. Mardis, L. Ding, B. Fulton, M.D. McLellan, K. Chen, et al., DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature 456, 66–72 (2008)
G. Ciriello, M.L. Miller, B.A. Aksoy, Y. Senbabaoglu, N. Schultz, C. Sander, Emerging landscape of oncogenic signatures across human cancers. Nat. Genet. 45, 1127–1133 (2013)
C.K. Zhou, D.P. Check, J. Lortet-Tieulent, M. Laversanne, A. Jemal, J. Ferlay, et al., Prostate cancer incidence in 43 populations worldwide: an analysis of time trends overall and by age group. Int. J. Cancer 138, 1388–1400 (2016)
I.F. Tannock, R. de Wit, W.R. Berry, J. Horti, A. Pluzanska, K.N. Chi, et al., Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med. 351, 1502–1512 (2004)
J. Armenia, S.A.M. Wankowicz, D. Liu, J. Gao, R. Kundra, E. Reznik, et al., The long tail of oncogenic drivers in prostate cancer. Nat. Genet. 50, 645–651 (2018)
M.F. Berger, M.S. Lawrence, F. Demichelis, Y. Drier, K. Cibulskis, A.Y. Sivachenko, et al., The genomic complexity of primary human prostate cancer. Nature 470, 214–220 (2011)
H. Muller, Androgen-control therapy in carcinoma of prostate. Arch. Chir. Neerl. 1, 77–88 (1949)
T.H. van der Kwast, J. Schalken, J.A. Ruizeveld de Winter, C.C. van Vroonhoven, E. Mulder, W. Boersma, et al., Androgen receptors in endocrine-therapy-resistant human prostate cancer. Int. J. Cancer 48, 189–193 (1991)
M.E. Taplin, G.J. Bubley, T.D. Shuster, M.E. Frantz, A.E. Spooner, G.K. Ogata, et al., Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N. Engl. J. Med. 332, 1393–1398 (1995)
J.P. Gaddipati, D.G. McLeod, H.B. Heidenberg, I.A. Sesterhenn, M.J. Finger, J.W. Moul, et al., Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers. Cancer Res. 54, 2861–2864 (1994)
G. Petrovics, A. Liu, S. Shaheduzzaman, B. Furusato, C. Sun, Y. Chen, et al., Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome. Oncogene 24, 3847–3852 (2005)
S.A. Tomlins, D.R. Rhodes, S. Perner, S.M. Dhanasekaran, R. Mehra, X.W. Sun, et al., Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310, 644–648 (2005)
M. Yoshimoto, A.M. Joshua, S. Chilton-Macneill, J. Bayani, S. Selvarajah, A.J. Evans, et al., Three-color FISH analysis of TMPRSS2/ERG fusions in prostate cancer indicates that genomic microdeletion of chromosome 21 is associated with rearrangement. Neoplasia 8, 465–469 (2006)
Cancer Genome Atlas Research N, The molecular taxonomy of primary prostate cancer. Cell 163, 1011–1025 (2015)
S.A. Tomlins, N. Palanisamy, J. Siddiqui, A.M. Chinnaiyan, L.P. Kunju, Antibody-based detection of ERG rearrangements in prostate core biopsies, including diagnostically challenging cases: ERG staining in prostate core biopsies. Arch. Pathol. Lab. Med. 136, 935–946 (2012)
K. Park, S.A. Tomlins, K.M. Mudaliar, Y.L. Chiu, R. Esgueva, R. Mehra, et al., Antibody-based detection of ERG rearrangement-positive prostate cancer. Neoplasia 12, 590–598 (2010)
K.D. Mertz, S.R. Setlur, S.M. Dhanasekaran, F. Demichelis, S. Perner, S. Tomlins, et al., Molecular characterization of TMPRSS2-ERG gene fusion in the NCI-H660 prostate cancer cell line: a new perspective for an old model. Neoplasia 9, 200–206 (2007)
S.J. Baker, E.P. Reddy, Understanding the temporal sequence of genetic events that lead to prostate cancer progression and metastasis. Proc. Natl. Acad. Sci. U. S. A. 110, 14819–14820 (2013)
A. Dal Pra, E. Lalonde, J. Sykes, F. Warde, A. Ishkanian, A. Meng, et al., TMPRSS2-ERG status is not prognostic following prostate cancer radiotherapy: implications for fusion status and DSB repair. Clin. Cancer Res. 19, 5202–5209 (2013)
S. Minner, M. Enodien, H. Sirma, A.M. Luebke, A. Krohn, P.S. Mayer, et al., ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy. Clin. Cancer Res. 17, 5878–5888 (2011)
K.J. Kron, A. Murison, S. Zhou, V. Huang, T.N. Yamaguchi, Y.J. Shiah, et al., TMPRSS2-ERG fusion co-opts master transcription factors and activates NOTCH signaling in primary prostate cancer. Nat. Genet. 49(9), 1336–1345 (2017)
S.C. Baca, D. Prandi, M.S. Lawrence, J.M. Mosquera, A. Romanel, Y. Drier, et al., Punctuated evolution of prostate cancer genomes. Cell 153, 666–677 (2013)
M. Fraser, V.Y. Sabelnykova, T.N. Yamaguchi, L.E. Heisler, J. Livingstone, V. Huang, et al., Genomic hallmarks of localized, non-indolent prostate cancer. Nature 541(7637), 359–364 (2017)
J. Weischenfeldt, R. Simon, L. Feuerbach, K. Schlangen, D. Weichenhan, S. Minner, et al., Integrative genomic analyses reveal an androgen-driven somatic alteration landscape in early-onset prostate cancer. Cancer Cell 23, 159–170 (2013)
D.A. Quigley, H.X. Dang, S.G. Zhao, P. Lloyd, R. Aggarwal, J.J. Alumkal, et al., Genomic hallmarks and structural variation in metastatic prostate cancer. Cell 174, 758–69.e9 (2018)
D. Robinson, E.M. Van Allen, Y.M. Wu, N. Schultz, R.J. Lonigro, J.M. Mosquera, et al., Integrative clinical genomics of advanced prostate cancer. Cell 161, 1215–1228 (2015)
C.S. Grasso, Y.M. Wu, D.R. Robinson, X. Cao, S.M. Dhanasekaran, A.P. Khan, et al., The mutational landscape of lethal castration-resistant prostate cancer. Nature 487, 239–243 (2012)
G. Boysen, D. Nava Rodrigues, P. Rescigno, G. Seed, D.I. Dolling, R. Riisnaes, et al., SPOP mutated/CHD1 deleted lethal prostate cancer and abiraterone sensitivity. Clin. Cancer Res. 24(22), 5585–5593 (2018)
R. Mehra, B. Han, S.A. Tomlins, L. Wang, A. Menon, M.J. Wasco, et al., Heterogeneity of TMPRSS2 gene rearrangements in multifocal prostate adenocarcinoma: molecular evidence for an independent group of diseases. Cancer Res. 67, 7991–7995 (2007)
X. Wang, Y. Qiao, I.A. Asangani, B. Ateeq, A. Poliakov, M. Cieslik, et al., Development of peptidomimetic inhibitors of the ERG gene fusion product in prostate cancer. Cancer Cell 31, 532–48.e7 (2017)
J.C. Brenner, B. Ateeq, Y. Li, A.K. Yocum, Q. Cao, I.A. Asangani, et al., Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer. Cancer Cell 19, 664–678 (2011)
S. Steurer, P.S. Mayer, M. Adam, A. Krohn, C. Koop, D. Ospina-Klinck, et al., TMPRSS2-ERG fusions are strongly linked to young patient age in low-grade prostate cancer. Eur. Urol. 66, 978–981 (2014)
L.C. Trotman, M. Niki, Z.A. Dotan, J.A. Koutcher, A. Di Cristofano, A. Xiao, et al., Pten dose dictates cancer progression in the prostate. PLoS Biol. 1, E59 (2003)
S. Ren, Z. Peng, J.H. Mao, Y. Yu, C. Yin, X. Gao, et al., RNA-seq analysis of prostate cancer in the Chinese population identifies recurrent gene fusions, cancer-associated long noncoding RNAs and aberrant alternative splicings. Cell Res. 22, 806–821 (2012)
D.C. Wedge, G. Gundem, T. Mitchell, D.J. Woodcock, I. Martincorena, M. Ghori, et al., Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets. Nat. Genet. 50, 682–692 (2018)
S. Ren, G.H. Wei, D. Liu, L. Wang, Y. Hou, S. Zhu, et al., Whole-genome and transcriptome sequencing of prostate cancer identify new genetic alterations driving disease progression. Eur. Urol. (2017)
N. Heisterkamp, K. Stam, J. Groffen, A. de Klein, G. Grosveld, Structural organization of the bcr gene and its role in the Ph’ translocation. Nature 315, 758–761 (1985)
J.L. Hecht, J.C. Aster, Molecular biology of Burkitt’s lymphoma. J. Clin. Oncol. 18, 3707–3721 (2000)
S.M. Kornblau, A. Goodacre, F. Cabanillas, Chromosomal abnormalities in adult non-endemic Burkitt’s lymphoma and leukemia: 22 new reports and a review of 148 cases from the literature. Hematol. Oncol. 9, 63–78 (1991)
G. Kaur, R. Gupta, N. Mathur, L. Rani, L. Kumar, A. Sharma, et al., Clinical impact of chromothriptic complex chromosomal rearrangements in newly diagnosed multiple myeloma. Leuk. Res. 76, 58–64 (2019)
N.D. Anderson, R. de Borja, M.D. Young, F. Fuligni, A. Rosic, N.D. Roberts, et al., Rearrangement bursts generate canonical gene fusions in bone and soft tissue tumors. Science 361, eaam8419 (2018)
A. Steininger, G. Ebert, B.V. Becker, C. Assaf, M. Mobs, C.A. Schmidt, et al., Genome-wide analysis of interchromosomal interaction probabilities reveals chained translocations and overrepresentation of translocation breakpoints in genes in a cutaneous T-cell lymphoma cell line. Front. Oncol. 8, 183 (2018)
Z. Wang, Y. Cheng, J.M. Abraham, R. Yan, X. Liu, W. Chen, et al., RNA sequencing of esophageal adenocarcinomas identifies novel fusion transcripts, including NPC1-MELK, arising from a complex chromosomal rearrangement. Cancer 123, 3916–3924 (2017)
J.K. Lee, S. Louzada, Y. An, S.Y. Kim, S. Kim, J. Youk, et al., Complex chromosomal rearrangements by single catastrophic pathogenesis in NUT midline carcinoma. Ann. Oncol. 28, 890–897 (2017)
V. Bhandari, C. Hoey, L.Y. Liu, E. Lalonde, J. Ray, J. Livingstone, et al., Molecular landmarks of tumor hypoxia across cancer types. Nat Genet 51(2), 308–318 (2019)
V. Stambolic, A. Suzuki, J.L. de la Pompa, G.M. Brothers, C. Mirtsos, T. Sasaki, et al., Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 95, 29–39 (1998)
A.M. Mendes-Pereira, S.A. Martin, R. Brough, A. McCarthy, J.R. Taylor, J.S. Kim, et al., Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO Mol. Med. 1, 315–322 (2009)
M.D. Forster, K.J. Dedes, S. Sandhu, S. Frentzas, R. Kristeleit, A. Ashworth, et al., Treatment with olaparib in a patient with PTEN-deficient endometrioid endometrial cancer. Nat. Rev. Clin. Oncol. 8, 302–306 (2011)
K.J. Dedes, D. Wetterskog, A.M. Mendes-Pereira, R. Natrajan, M.B. Lambros, F.C. Geyer, et al., PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors. Sci. Transl. Med. 2, 53ra75 (2010)
A. Gupta, Q. Yang, R.K. Pandita, C.R. Hunt, T. Xiang, S. Misri, et al., Cell cycle checkpoint defects contribute to genomic instability in PTEN deficient cells independent of DNA DSB repair. Cell Cycle 8, 2198–2210 (2009)
B. McEllin, C.V. Camacho, B. Mukherjee, B. Hahm, N. Tomimatsu, R.M. Bachoo, et al., PTEN loss compromises homologous recombination repair in astrocytes: implications for glioblastoma therapy with temozolomide or poly(ADP-ribose) polymerase inhibitors. Cancer Res. 70, 5457–5464 (2010)
M. Fraser, H. Zhao, K.R. Luoto, C. Lundin, C. Coackley, N. Chan, et al., PTEN deletion in prostate cancer cells does not associate with loss of RAD51 function: implications for radiotherapy and chemotherapy. Clin. Cancer Res. 18, 1015–1027 (2012)
M. Zimmermann, O. Murina, M.A.M. Reijns, A. Agathanggelou, R. Challis, Z. Tarnauskaite, et al., CRISPR screens identify genomic ribonucleotides as a source of PARP-trapping lesions. Nature 559, 285–289 (2018)
S.M.G. Espiritu, L.Y. Liu, Y. Rubanova, V. Bhandari, E.M. Holgersen, L.M. Szyca, et al., The evolutionary landscape of localized prostate cancers drives clinical aggression. Cell 173, 1003–13.e15 (2018)
P.C. Boutros, M. Fraser, N.J. Harding, R. de Borja, D. Trudel, E. Lalonde, et al., Spatial genomic heterogeneity within localized, multifocal prostate cancer. Nat. Genet. 47, 736–745 (2015)
L. Burkhardt, S. Fuchs, A. Krohn, S. Masser, M. Mader, M. Kluth, et al., CHD1 is a 5q21 tumor suppressor required for ERG rearrangement in prostate cancer. Cancer Res. 73, 2795–2805 (2013)
W. Gan, X. Dai, A. Lunardi, Z. Li, H. Inuzuka, P. Liu, et al., SPOP promotes ubiquitination and degradation of the ERG oncoprotein to suppress prostate cancer progression. Mol. Cell 59, 917–930 (2015)
J. An, S. Ren, S.J. Murphy, S. Dalangood, C. Chang, X. Pang, et al., Truncated ERG oncoproteins from TMPRSS2-ERG fusions are resistant to SPOP-mediated proteasome degradation. Mol. Cell 59, 904–916 (2015)
E. Muhlbradt, E. Asatiani, E. Ortner, A. Wang, E.P. Gelmann, NKX3.1 activates expression of insulin-like growth factor binding protein-3 to mediate insulin-like growth factor-I signaling and cell proliferation. Cancer Res. 69, 2615–2622 (2009)
J.A. Locke, G. Zafarana, A.S. Ishkanian, M. Milosevic, J. Thoms, C.L. Have, et al., NKX3.1 haploinsufficiency is prognostic for prostate cancer relapse following surgery or image-guided radiotherapy. Clin. Cancer Res. 18, 308–316 (2012)
G. Zafarana, A.S. Ishkanian, C.A. Malloff, J.A. Locke, J. Sykes, J. Thoms, et al., Copy number alterations of c-MYC and PTEN are prognostic factors for relapse after prostate cancer radiotherapy. Cancer 118, 4053–4062 (2012)
E. Castro, S. Jugurnauth-Little, Q. Karlsson, F. Al-Shahrour, E. Pineiro-Yanez, F. Van de Poll, et al., High burden of copy number alterations and c-MYC amplification in prostate cancer from BRCA2 germline mutation carriers. Ann. Oncol. 26, 2293–2300 (2015)
R.A. Taylor, M. Fraser, J. Livingstone, S.M. Espiritu, H. Thorne, V. Huang, et al., Germline BRCA2 mutations drive prostate cancers with distinct evolutionary trajectories. Nat. Commun. 8, 13671 (2017)
G.P. Risbridger, R.A. Taylor, D. Clouston, A. Sliwinski, H. Thorne, S. Hunter, et al., Patient-derived xenografts reveal that intraductal carcinoma of the prostate is a prominent pathology in BRCA2 mutation carriers with prostate cancer and correlates with poor prognosis. Eur. Urol. 67, 496–503 (2015)
A. Berlin, E. Lalonde, J. Sykes, G. Zafarana, K.C. Chu, V.R. Ramnarine, et al., NBN gain is predictive for adverse outcome following image-guided radiotherapy for localized prostate cancer. Oncotarget 5, 11081–11090 (2014)
H. Guo, M. Ahmed, F. Zhang, C.Q. Yao, S. Li, Y. Liang, et al., Modulation of long noncoding RNAs by risk SNPs underlying genetic predispositions to prostate cancer. Nat. Genet. 48, 1142–1150 (2016)
B. Le Tallec, G.A. Millot, M.E. Blin, O. Brison, B. Dutrillaux, M. Debatisse, Common fragile site profiling in epithelial and erythroid cells reveals that most recurrent cancer deletions lie in fragile sites hosting large genes. Cell Rep. 4, 420–428 (2013)
J.R. Prensner, W. Chen, S. Han, M.K. Iyer, Q. Cao, V. Kothari, et al., The long non-coding RNA PCAT-1 promotes prostate cancer cell proliferation through cMyc. Neoplasia 16, 900–908 (2014)
W. Zhang, B. Liu, W. Wu, L. Li, B.M. Broom, S.P. Basourakos, et al., Targeting the MYCN-PARP-DNA damage response pathway in neuroendocrine prostate cancer. Clin. Cancer Res. 24, 696–707 (2018)
J.M. Mosquera, H. Beltran, K. Park, T.Y. MacDonald, B.D. Robinson, S.T. Tagawa, et al., Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancer. Neoplasia 15, 1–10 (2013)
J. Edwards, N.S. Krishna, C.J. Witton, J.M. Bartlett, Gene amplifications associated with the development of hormone-resistant prostate cancer. Clin. Cancer Res. 9, 5271–5281 (2003)
E. Lalonde, A.S. Ishkanian, J. Sykes, M. Fraser, H. Ross-Adams, N. Erho, et al., Tumor genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: a retrospective cohort study. Lancet Oncol. 15, 1521–1532 (2014)
H. Hieronymus, N. Schultz, A. Gopalan, B.S. Carver, M.T. Chang, Y. Xiao, et al., Copy number alteration burden predicts prostate cancer relapse. Proc. Natl. Acad. Sci. U. S. A. 111, 11139–11144 (2014)
E. Lalonde, R. Alkallas, M.L. Chua, M. Fraser, S. Haider, A. Meng, et al., Translating a prognostic DNA genomic classifier into the clinic: retrospective validation in 563 localized prostate tumors. Eur. Urol. 72(1), 22–31 (2017)
W.P. Kloosterman, V. Guryev, M. van Roosmalen, K.J. Duran, E. de Bruijn, S.C. Bakker, et al., Chromothripsis as a mechanism driving complex de novo structural rearrangements in the germline. Hum. Mol. Genet. 20, 1916–1924 (2011)
P.J. Stephens, C.D. Greenman, B. Fu, F. Yang, G.R. Bignell, L.J. Mudie, et al., Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell 144, 27–40 (2011)
S.K. Govind, A. Zia, P.H. Hennings-Yeomans, J.D. Watson, M. Fraser, C. Anghel, et al., ShatterProof: operational detection and quantification of chromothripsis. BMC Bioinformatics 15, 78 (2014)
J.R. Federer-Gsponer, C. Quintavalle, D.C. Muller, T. Dietsche, V. Perrina, T. Lorber, et al., Delineation of human prostate cancer evolution identifies chromothripsis as a polyclonal event and FKBP4 as a potential driver of castration resistance. J. Pathol. 245, 74–84 (2018)
C. Wu, A.W. Wyatt, A. McPherson, D. Lin, B.J. McConeghy, F. Mo, et al., Poly-gene fusion transcripts and chromothripsis in prostate cancer. Genes Chromosomes Cancer 51, 1144–1153 (2012)
D. Nava Rodrigues, P. Rescigno, D. Liu, W. Yuan, S. Carreira, M.B. Lambros, et al., Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer. J. Clin. Invest. 128, 4441–4453 (2018)
T.A. Knijnenburg, L. Wang, M.T. Zimmermann, N. Chambwe, G.F. Gao, A.D. Cherniack, et al., Genomic and molecular landscape of DNA damage repair deficiency across the cancer genome atlas. Cell Rep 23, 239–54.e6 (2018)
Y.M. Wu, M. Cieslik, R.J. Lonigro, P. Vats, M.A. Reimers, X. Cao, et al., Inactivation of CDK12 delineates a distinct immunogenic class of advanced prostate cancer. Cell 173, 1770–82.e14 (2018)
M. Noguchi, T.A. Stamey, J.E. McNeal, R. Nolley, Prognostic factors for multifocal prostate cancer in radical prostatectomy specimens: lack of significance of secondary cancers. J. Urol. 170, 459–463 (2003)
A.M. Wise, T.A. Stamey, J.E. McNeal, J.L. Clayton, Morphologic and clinical significance of multifocal prostate cancers in radical prostatectomy specimens. Urology 60, 264–269 (2002)
L. Wei, J. Wang, E. Lampert, S. Schlanger, A.D. DePriest, Q. Hu, et al., Intratumoral and intertumoral genomic heterogeneity of multifocal localized prostate cancer impacts molecular classifications and genomic prognosticators. Eur. Urol. 71, 183–192 (2017)
D. Brocks, Y. Assenov, S. Minner, O. Bogatyrova, R. Simon, C. Koop, et al., Intratumor DNA methylation heterogeneity reflects clonal evolution in aggressive prostate cancer. Cell Rep. 8, 798–806 (2014)
C.S. Cooper, R. Eeles, D.C. Wedge, P. Van Loo, G. Gundem, L.B. Alexandrov, et al., Analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue. Nat. Genet. 47, 367–372 (2015)
M. Lovf, S. Zhao, U. Axcrona, B. Johannessen, A.C. Bakken, K.T. Carm, et al., Multifocal primary prostate cancer exhibits high degree of genomic heterogeneity. Eur. Urol. 75(3), 498–505 (2019)
D. Nava Rodrigues, N. Casiraghi, A. Romanel, M. Crespo, S. Miranda, P. Rescigno, et al., RB1 heterogeneity in advanced metastatic castration-resistant prostate cancer. Clin. Cancer Res. 25, 687–697 (2019)
M.C. Haffner, T. Mosbruger, D.M. Esopi, H. Fedor, C.M. Heaphy, D.A. Walker, et al., Tracking the clonal origin of lethal prostate cancer. J. Clin. Invest. 123, 4918–4922 (2013)
G. Gundem, P. Van Loo, B. Kremeyer, L.B. Alexandrov, J.M. Tubio, E. Papaemmanuil, et al., The evolutionary history of lethal metastatic prostate cancer. Nature 520, 353–357 (2015)
J. Kneppers, O. Krijgsman, M. Melis, J. de Jong, D.S. Peeper, E. Bekers, et al., Frequent clonal relations between metastases and non-index prostate cancer lesions. JCI Insight. 4, 124756 (2019)
S. Nik-Zainal, L.B. Alexandrov, D.C. Wedge, P. Van Loo, C.D. Greenman, K. Raine, et al., Mutational processes molding the genomes of 21 breast cancers. Cell 149, 979–993 (2012)
C. Gerhauser, F. Favero, T. Risch, R. Simon, L. Feuerbach, Y. Assenov, et al., Molecular evolution of early-onset prostate cancer identifies molecular risk markers and clinical trajectories. Cancer Cell 34, 996–1011.e8 (2018)
A. McPherson, A. Roth, E. Laks, T. Masud, A. Bashashati, A.W. Zhang, et al., Divergent modes of clonal spread and intraperitoneal mixing in high-grade serous ovarian cancer. Nat. Genet. 48, 758–767 (2016)
A.W. Zhang, A. McPherson, K. Milne, D.R. Kroeger, P.T. Hamilton, A. Miranda, et al., Interfaces of malignant and immunologic clonal dynamics in ovarian cancer. Cell 173, 1755–69.e22 (2018)
C. Abbosh, N.J. Birkbak, G.A. Wilson, M. Jamal-Hanjani, T. Constantin, R. Salari, et al., Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature 545, 446–451 (2017)
S. Roemeling, M.J. Roobol, S.H. de Vries, C. Gosselaar, T.H. van der Kwast, F.H. Schroder, Prevalence, treatment modalities and prognosis of familial prostate cancer in a screened population. J. Urol. 175, 1332–1336 (2006)
S. Kommu, S. Edwards, R. Eeles, The clinical genetics of prostate cancer. Hered. Cancer Clin. Pract. 2, 111–121 (2004)
C. Breast Cancer Linkage, Cancer risks in BRCA2 mutation carriers. J. Natl. Cancer Inst. 91, 1310–1316 (1999)
C.C. Pritchard, J. Mateo, M.F. Walsh, N. De Sarkar, W. Abida, H. Beltran, et al., Inherited DNA-repair gene mutations in men with metastatic prostate cancer. N. Engl. J. Med. 375, 443–453 (2016)
L. Briollais, H. Ozcelik, J. Xu, M. Kwiatkowski, E. Lalonde, D.H. Sendorek, et al., Germline mutations in the Kallikrein 6 region and predisposition for aggressive prostate cancer. J. Natl. Cancer Inst. 109 (2017)
N.C. Turner, C.J. Lord, E. Iorns, R. Brough, S. Swift, R. Elliott, et al., A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor. EMBO J. 27, 1368–1377 (2008)
J. Mateo, S. Carreira, S. Sandhu, S. Miranda, H. Mossop, R. Perez-Lopez, et al., DNA-repair defects and olaparib in metastatic prostate cancer. N. Engl. J. Med. 373, 1697–1708 (2015)
T. Dadaev, E.J. Saunders, P.J. Newcombe, E. Anokian, D.A. Leongamornlert, M.N. Brook, et al., Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants. Nat. Commun. 9, 2256 (2018)
F.R. Schumacher, A.A. Al Olama, S.I. Berndt, S. Benlloch, M. Ahmed, E.J. Saunders, et al., Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. Nat. Genet. 50, 928–936 (2018)
P. Isaacsson Velho, J.L. Silberstein, M.C. Markowski, J. Luo, T.L. Lotan, W.B. Isaacs, et al., Intraductal/ductal histology and lymphovascular invasion are associated with germline DNA-repair gene mutations in prostate cancer. Prostate 78, 401–407 (2018)
R. Bottcher, C.F. Kweldam, J. Livingstone, E. Lalonde, T.N. Yamaguchi, V. Huang, et al., Cribriform and intraductal prostate cancer are associated with increased genomic instability and distinct genomic alterations. BMC Cancer 18, 8 (2018)
B.S. Taylor, N. Schultz, H. Hieronymus, A. Gopalan, Y. Xiao, B.S. Carver, et al., Integrative genomic profiling of human prostate cancer. Cancer Cell 18, 11–22 (2010)
H. Hieronymus, R. Murali, A. Tin, K. Yadav, W. Abida, H. Moller, et al., Tumor copy number alteration burden is a pan-cancer prognostic factor associated with recurrence and death. elife 7, e37294 (2018)
M. Kluth, S. Harasimowicz, L. Burkhardt, K. Grupp, A. Krohn, K. Prien, et al., Clinical significance of different types of p53 gene alteration in surgically treated prostate cancer. Int. J. Cancer 135, 1369–1380 (2014)
B. De Laere, S. Oeyen, M. Mayrhofer, T. Whitington, P.J. van Dam, P. Van Oyen, et al., TP53 outperforms other androgen receptor biomarkers to predict abiraterone or enzalutamide outcome in metastatic castration-resistant prostate cancer. Clin. Cancer Res. 25(6), 1766–1773 (2019)
M.K. Buyyounouski, T. Pickles, L.L. Kestin, R. Allison, S.G. Williams, Validating the interval to biochemical failure for the identification of potentially lethal prostate cancer. J. Clin. Oncol. 30, 1857–1863 (2012)
W.C. Jackson, K. Suresh, V. Tumati, S.G. Allen, R.T. Dess, S.S. Salami, et al., Intermediate endpoints after postprostatectomy radiotherapy: 5-year distant metastasis to predict overall survival. Eur. Urol. 74(4), 413–419 (2018)
E. Olkhov-Mitsel, F. Siadat, K. Kron, L. Liu, A.J. Savio, J. Trachtenberg, et al., Distinct DNA methylation alterations are associated with cribriform architecture and intraductal carcinoma in Gleason pattern 4 prostate tumors. Oncol. Lett. 14, 390–396 (2017)
S.N. Kamdar, L.T. Ho, K.J. Kron, R. Isserlin, T. van der Kwast, A.R. Zlotta, et al., Dynamic interplay between locus-specific DNA methylation and hydroxymethylation regulates distinct biological pathways in prostate carcinogenesis. Clin. Epigenetics 8, 32 (2016)
N.M. White-Al Habeeb, L.T. Ho, E. Olkhov-Mitsel, K. Kron, V. Pethe, M. Lehman, et al., Integrated analysis of epigenomic and genomic changes by DNA methylation dependent mechanisms provides potential novel biomarkers for prostate cancer. Oncotarget 5, 7858–7869 (2014)
E. Olkhov-Mitsel, D. Zdravic, K. Kron, T. van der Kwast, N. Fleshner, B. Bapat, Novel multiplex MethyLight protocol for detection of DNA methylation in patient tissues and bodily fluids. Sci. Rep. 4, 4432 (2014)
K. Kron, D. Trudel, V. Pethe, L. Briollais, N. Fleshner, T. van der Kwast, et al., Altered DNA methylation landscapes of polycomb-repressed loci are associated with prostate cancer progression and ERG oncogene expression in prostate cancer. Clin. Cancer Res. 19, 3450–3461 (2013)
E. Olkhov-Mitsel, T. Van der Kwast, K.J. Kron, H. Ozcelik, L. Briollais, C. Massey, et al., Quantitative DNA methylation analysis of genes coding for kallikrein-related peptidases 6 and 10 as biomarkers for prostate cancer. Epigenetics 7, 1037–1045 (2012)
K. Kron, L. Liu, D. Trudel, V. Pethe, J. Trachtenberg, N. Fleshner, et al., Correlation of ERG expression and DNA methylation biomarkers with adverse clinicopathologic features of prostate cancer. Clin. Cancer Res. 18, 2896–2904 (2012)
L. Liu, K.J. Kron, V.V. Pethe, N. Demetrashvili, M.E. Nesbitt, J. Trachtenberg, et al., Association of tissue promoter methylation levels of APC, TGFbeta2, HOXD3 and RASSF1A with prostate cancer progression. Int. J. Cancer 129, 2454–2462 (2011)
K.J. Kron, L. Liu, V.V. Pethe, N. Demetrashvili, M.E. Nesbitt, J. Trachtenberg, et al., DNA methylation of HOXD3 as a marker of prostate cancer progression. Lab. Investig. 90, 1060–1067 (2010)
K. Kron, V. Pethe, L. Briollais, B. Sadikovic, H. Ozcelik, A. Sunderji, et al., Discovery of novel hypermethylated genes in prostate cancer using genomic CpG island microarrays. PLoS One 4, e4830 (2009)
G. Vandekerkhove, W.J. Struss, M. Annala, K. HML, D. Khalaf, E.W. Warner, et al., Circulating tumor DNA abundance and potential utility in de novo metastatic prostate cancer. Eur. Urol. 75(4), 667–675 (2019)
M. Annala, G. Vandekerkhove, D. Khalaf, S. Taavitsainen, K. Beja, E.W. Warner, et al., Circulating tumor DNA genomics correlate with resistance to abiraterone and enzalutamide in prostate cancer. Cancer Discov. 8, 444–457 (2018)
E. Ritch, A.W. Wyatt, Predicting therapy response and resistance in metastatic prostate cancer with circulating tumor DNA. Urol. Oncol. 36, 380–384 (2018)
G. Vandekerkhove, K.N. Chi, A.W. Wyatt, Clinical utility of emerging liquid biomarkers in advanced prostate cancer. Cancer Genet. 228-229, 151–158 (2018)
N. Camacho, P. Van Loo, S. Edwards, J.D. Kay, L. Matthews, K. Haase, et al., Appraising the relevance of DNA copy number loss and gain in prostate cancer using whole genome DNA sequence data. PLoS Genet. 13, e1007001 (2017)
F. Su, W. Zhang, D. Zhang, Y. Zhang, C. Pang, Y. Huang, et al., Spatial intratumor genomic heterogeneity within localized prostate cancer revealed by single-nucleus sequencing. Eur. Urol. 74(5), 551–559 (2018)
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Fraser, M., Rouette, A. (2019). Prostate Cancer Genomic Subtypes. In: Dehm, S., Tindall, D. (eds) Prostate Cancer. Advances in Experimental Medicine and Biology, vol 1210. Springer, Cham. https://doi.org/10.1007/978-3-030-32656-2_5
Download citation
DOI: https://doi.org/10.1007/978-3-030-32656-2_5
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-32655-5
Online ISBN: 978-3-030-32656-2
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)